Université Catholique de Louvain
Quick facts
Marketed products
- Bisphosphonate treatment
- Infliximab, methylprednisolone, methotrexate · Immunology
This combination suppresses TNF-α signaling and T-cell proliferation to reduce inflammatory immune responses in autoimmune diseases. - Methotrexate + Infliximab · Immunology / Rheumatology
Methotrexate suppresses immune cell proliferation while infliximab blocks tumor necrosis factor-alpha, together reducing inflammatory and autoimmune responses. - Methotrexate + Methylprednisolone · Immunology / Rheumatology
Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation and immune activation, while methylprednisolone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: